Gateway to Oz 2017_web assets_v1-1.jpg

As we look forward to celebrating Gateway to Oz, please enjoy this Sizzle Reel in commemoration of last year's unprecedented success!

We invite you to become a sponsor of the 2017 Cures Gala, Gateway to Oz,
the largest annual event benefiting Gateway!

Your sponsorship will allow us to continue our mission of funding meaningful and breakthrough clinical trials worldwide that help people living with cancer to feel better, live longer and conquer cancer TODAY!

WHEN: Saturday, November 18, 2017

TIME: Five O'clock in the Evening

WHERE
: Grand Ballroom, McCormick Place
2301 S. King Drive
Chicago, IL 60616

HONORARY CHAIR: Jim Gordon
HONORARY CO-CHAIRS:
Richard J Stephenson & Dr. Stacie J. Stephenson

The Emerald City-worthy event will rock with the legendary R&B band
that changed the sounds of pop for all times, Earth, Wind & Fire.

Click your heels along a magical journey, beginning with a unique culinary experience and followed by a first-class entertainment roster including Matteo Bocelli, son of Andrea Bocelli performing for the first time in Chicago; Billy Gilman, the youngest singer to ever reach #1 on the Billboard Top Country Album charts; Laura Breton, America’s Got Talent finalist and “Golden Buzzer” winner; and Letitia Frye, America’s foremost “auctiontainer.”  

Download sponsorship form here.

Hotel room blocks available at:
Hyatt Regency McCormick Place
Nightly rate of $179 | (312)-567-1234
W Lakeshore, Chicago
Nightly rate of $179 | (888)-627-9034

Valet Parking at McCormick Place is available along
with transportation from the following hotels:
The Langham & W Lakeshore Chicago
The Hyatt Regency is connected to McCormick Place

FORMAL ATTIRE

For more information, please contact events@gatewaycr.org,
or call 866-932-4208.


Sponsor      

 

99 cents of every dollar received directly funds cancer clinical trials

57

Current Gateway-funded clinical trials

150+

Clinical trials funded at leading institutions worldwide

$16.56

Funds one patient for one day at a Gateway-funded clinical trial

 
 

Mission Partners